All In Biotech

Drug Trial Radar · NCT07901751

Study to Evaluate the Efficacy of a Single Intravitreal Injection of RTx-015 in Participants With Retinitis Pigmentosa (PERCEPT)

Phase 2/3, Double-masked, Randomized, Sham-controlled, Single Dose Study to Evaluate the Efficacy of a Single Intravitreal Injection of RTx-015 in Participants With Retinitis Pigmentosa (PERCEPT)

Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Oct 2026

Primary completion

Oct 2028

Study completion Oct 2028

Sponsor

Lead sponsor
Ray Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Oct 28, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this clinical trial is to evaluate the effectiveness and safety of a single injection into the eye of an investigational gene therapy in participants with retinitis pigmentosa (RP).

Conditions

  • Retinitis Pigmentosa (RP)
  • Inherited Retinal Diseases

Interventions

  • RTx-015Drug

    Intravitreal injection

  • Sham ControlOther

    Sham Control

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary ObjectiveTime frame: 12 Months

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • RayTx Clinical Site

    Phoenix, Arizona · Not yet recruiting

  • RayTx Clinical Site

    Bakersfield, California · Recruiting

  • RayTx Clinical Site

    Beverly Hills, California · Recruiting

  • RayTx Clinical Site

    Santa Barbara, California · Not yet recruiting

  • RayTx Clinical Site

    Deerfield Beach, Florida · Not yet recruiting

  • RayTx Clinical Site

    ‘Aiea, Hawaii · Not yet recruiting

  • RayTx Clinical Site

    Oak Park, Illinois · Recruiting

  • RayTx Clinical Site

    Detroit, Michigan · Not yet recruiting

  • RayTx Clinical Site

    Edina, Minnesota · Not yet recruiting

  • RayTx Clinical Site

    Bloomfield, New Jersey · Not yet recruiting

  • RayTx Clinical Site

    Greensboro, North Carolina · Recruiting

  • RayTx Clinical Site

    Portland, Oregon · Recruiting

  • RayTx Clinical Site

    Mt. Pleasant, South Carolina · Recruiting

  • RayTx Clinical Site

    San Antonio, Texas · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.